Cuba: The first group of 25 children between the ages of three and 11 included in Cuba’s anti-Covid-19 clinical trial, called Soberana Pediatría, received the first dose of the vaccine candidate Soberana 02 today, reports Radio Rebelde.
As detailed by authorities from the Finlay Vaccine Institute, the project’s development center, the selection of the small volunteers was carried out after the safety of the initial injection of Soberana 02 in 25 adolescents between 12 and 18 years of age was verified.
The Deputy Director of the aforementioned institution, Yury Valdés, explained that this last group was followed up at 24, 48, 72 hours and a week after immunization.
The clinical study will have a total of 350 subjects ranging from ages three to 18, who will be administered two doses of Soberana 02 and one of Soberana Plus, separated by an interval of 28 days.
